Access through your institution Buy or subscribe Overactivity of the transcription factor MYC plays a central part in the progression of multiple myeloma through upregulation of ribosome

synthesis and translation activity. Using a high-throughput screening approach, Manier _et al_. have identified a series of synthetic analogues of the rocaglate natural product class, which

potently inhibited proliferation of multiple myeloma cell lines that overexpress MYC. CMLD010509, the most potent rocaglate, selectively downregulated the oncogenic MYC-driven translation

programme in multiple myeloma cells. In mouse models of multiple myeloma, twice-weekly injection of CMLD010509 for 4 weeks reduced tumour burden and prolonged survival. This is a preview of

Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS:

* Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support REFERENCES * Manier, S. et al. Inhibiting the oncogenic translation program is an effective

therapeutic strategy in multiple myeloma. _Sci. Transl Med_. 9, eaal2668 (2017). Article  PubMed  PubMed Central  Google Scholar  Download references Authors * Sarah Crunkhorn View author

publications You can also search for this author inPubMed Google Scholar RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Crunkhorn, S. Targeting

MYC-driven translation. _Nat Rev Drug Discov_ 16, 456 (2017). https://doi.org/10.1038/nrd.2017.118 Download citation * Published: 16 June 2017 * Issue Date: July 2017 * DOI:

https://doi.org/10.1038/nrd.2017.118 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not

currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative